At Xenios, a Fresenius Medical Care company, we offer treatments for patients suffering from cardiac and/or pulmonary failure. Based on a holistic understanding of human physiology, we develop intelligent technological solutions that can be vital for the survival of critically ill patients.
We offer solutions that combine both cardiac and pulmonary support on one single technological platform. It supports the gas exchange in the lungs and the cardiovascular system to keep patients alive. The physician thus gains more vital treatment time during diagnosis and therapy.
Xenios is part of Fresenius Medical Care, the world's leading provider of products and services for people with renal diseases. We are complementing Fresenius Medical Care’s product portfolio in the field of intensive care and are continuing to shape the future of extracorporeal multi-organ support.
In our daily work, we share a passion for helping people. For patients. Worldwide. Every day.
Visit the Xenios website:
www.xenios-ag.com
Events
News
Xenios AG Receives Approval in China for ECMO Devices
2021 13 Jul
Xenios A6, a Fresenius Medical Care company, has received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China. It follows NMPA's approval of the Xenios console... Read more
Xenios AG Announces Changes in the Management Board
2021 31 Mar
The Management Board of Xenios AG , the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective January 31, 2021, the previous Chair of the Executive Board, Dr. Andreas Terpin, has left the company. The new senior trio on the Management Board will continue Fresenius Medical Care's success in the field of extracorporeal... Read more
iLA Membrane Ventilator Enables 36-Year-Old Woman To Survive 143 Days Until Lung Transplantation
2020 31 Aug
Doctors from General University Hospital in Prague saved the life of a 36-year-old woman and mother of a two-year-old child who urgently needed a lung transplant. She survived an incredible 143 days without a full working lung — due to the support of a device called iLA Membrane Ventilator. The iLA Membrane Ventilator is an extracorporeal ventilation... Read more
ECMO becomes crucial therapy in battle against COVID-19 in Europe - Xenios consoles as lifesavers
2020 30 Apr
As the coronavirus spreads and infections with COVID-19 further increase throughout Europe, ECMO therapy turns out to be a necessary option for patients with severe courses. Xenios AG , a subsidiary of Fresenius Medical Care, provides ECMO consoles that can be used for the treatment of patients who develop severe pneumonia and ARDS with lung... Read more
Novalung System Receives US FDA Clearance
2020 26 Feb
The US FDA (Food and Drug Administration) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for patients with acute lung failure or acute cardiopulmonary failure. The FDA announced this on Friday evening. With class II approval, the Novalung... Read more
Merger: Novalung Becomes Fully Integrated within Xenios
2019 02 Sep
Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care. Novalung was established in 2003 and specialises in the treatment of respiratory failure.... Read more
Synchronised Cardiovascular Support Now Ready for the Market
2019 10 Jul
Xenios AG concludes its first clinical study on i-cor Synchronized Cardiac Assist, documenting the safety and feasibility of the synchronized cardiovascular support system. During the “SynCor” trial, a multicentre study treated 47 patients in nine different German clinics using an innovative pulsatile, cardiac-synchronous circulatory support... Read more
Relaunch of the Xenios Website – Now harmonised with that of its parent, Fresenius Medical Care
2019 08 May
The Xenios AG, pioneer in extracorporeal heart and lung support, has restructured its website. Xenios AG has been part of the Fresenius Medical Care Group since 2016 and the new design also serves to bring the company visually in line with the brand image of its parent. www.xenios-ag.com With this newly structured website, the... Read more
Six Days Without a Lung – a Look into the Future of Medical Technology
2017 12 Apr
The dramatic story of Canadian Melissa Benoit, who lived for six days without a lung, shows a view of a new chapter in the history of medical technology. The novalung iLA membrane lung, which replaced the functions of the lung, is a product of XENIOS AG. As a strategic partner of XOR Labs in Toronto, both companies wanted to cooperate to revolutionize... Read more
Catalogue
White Papers - Case Studies
Videos
Articles
Blog
Content of this tab is based on company profile.
If you are logged in as company user or you are company editor then you can edit company profile here.
HEART & LUNG CAMPUS
JOIN – LEARN – CARE
Xenios console
universal - reliable - effective
Extracorporeal organ support for enhanced patient well-being Dedicated technology combines both heart and lung support in one single platform – a platform that is universally usable, individual, safe, and compatible with applications of our parent...
iLA Membrane Ventilator
The world’s only pumpless extrapulmonary gas exchange system
The iLA membrane ventilator is an extrapulmonary ventilation system which is used to remove carbon dioxide. The heart pumps blood through the iLA membrane ventilator as it does through a natural organ. The iLA membrane ventilator “breathes” outside...
NovaPort cannulas
The safe access to the vascular system
NovaPort cannulas are designed specially to meet the needs of extracorporeal heart and lung support circuits and perioperative perfusion in minimally invasive heart surgery. All blood-contact surfaces of the NovaPort cannulas are coated with the bio-...
iLA activve kits
Long-term lung support
Developed for long-term lung support - approved for 29 days of use Elementary features: • Proven reliability and safety • Certified for 29 days application period • Matching pump sizes for ¼ "" or 3/8"" tubing • x.ellence, a multi-layer coating...
Novalung kits
safe - simple - fast
Safe - Integrated pressure sensors (IPS) elevate your patients’ safety to the next level. Simple - Priming of the preconfigured kit requires just one person. Fast - Pump-driven priming in only two minutes. Elementary features:...
iLA acitvve iLA kit IPS
Long-term lung support - combine ECMO and CRRT
Especially developed for long-term lung support. This patient kit includes a powerful membrane lung, the DP3 pump head, safe integrated pressure sensors (IPS) and a CRRT connector. One vascular access offers the possibility to combine the therapies for...
support.sets
Standardized extracorporeal tubing set
Standardized extracorporeal tubing sets for short-term use • Standardized extracorporeal tubing set • Available in three different sizes (for infants, pediatrics and adults) • Approved for 6 hours of use • Rheoparin coating, the established Medos heparin...
MultiSupport GROUND
Transport of ECLS patients
The Xenios MultiSupport GROUND (MSG) is a system consisting of different components, designed to enable inner- and inter-hospital transport of severely ill patients undergoing life-saving extracorporeal heart and lung support. As a whole, the Xenios...